<DOC>
	<DOC>NCT03057951</DOC>
	<brief_summary>The aim of the study is to evaluate efficacy and safety of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with preserved ejection fraction</brief_summary>
	<brief_title>EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criteria: Male or female patient, age &gt;= 18 years at screening. For Japan only: Age &gt;=20 years at screening Patients with chronic HF (Chronic Heart Failure) NYHA (New York Heart Association classification) class IIIV and preserved EF (Ejection Fraction)(LVEF (Left Ventricular Ejection Fraction) &gt; 40 %) and elevated NTproBNP (Nterminal of the prohormone brain natriuretic peptide) &gt; 300 pg/ml for patients without AF, OR &gt; 900 pg/ml for patients with AF, analysed at the Central laboratory at Visit 1 Structural heart disease within 6 months prior to Visit 1, OR documented HHF (Hospitalisation for Heart Failure) within 12 months prior to Visit 1 Stable dose of oral diuretics, if prescribed Signed and dated written ICF (informed consent form) Further inclusion criteria apply Exclusion criteria: Myocardial infarction, coronary artery bypass graft surgery or other major cardiovascular surgery, stroke or TIA (Transient Ischaemic Attack) in past 90 days prior to Visit 1 Heart transplant recipient or listed for heart transplant Acute decompensated HF (Heart Failure) Systolic blood pressure (SBP) &gt;= 180 mmHg at Visit 2. Symptomatic hypotension and/or a SBP &lt; 100 mmHg Indication of liver disease, Impaired renal function, defined as eGFR (Estimated Glomerular Filtration Rate) &lt; 20 mL/min/1.73 m2 (CKDEPI (Chronic Kidney Disease Epidemiology Collaboration Equation))cr or requiring dialysis History of ketoacidosis Treatment with any SGLT (Sodiumglucose cotransporter) 2 inhibitor or combined SGLT1 and 2 inhibitor Currently enrolled in another investigational device or drug trial Known allergy or hypersensitivity to empagliflozin or other SGLT2 inhibitors Women who are pregnant, nursing, or who plan to become pregnant while in the trial Further exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>